Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3414663 | Microbes and Infection | 2014 | 6 Pages |
Abstract
Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13′ was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13′. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13′ can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacteremia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Iyo Takemura-Uchiyama, Jumpei Uchiyama, Makoto Osanai, Norihito Morimoto, Tadashi Asagiri, Takako Ujihara, Masanori Daibata, Tetsuro Sugiura, Shigenobu Matsuzaki,